Kevin Sayer Sells 26,759 Shares of DexCom (NASDAQ:DXCM) Stock

DexCom, Inc. (NASDAQ:DXCM) insider Kevin Sayer sold 26,759 shares of DexCom stock in a transaction that occurred on Thursday, May 21st. The shares were sold at an average price of $72.00, for a total transaction of $1,926,648.00. Following the completion of the sale, the insider owned 382,482 shares of the company’s stock, valued at $27,538,704. This trade represents a 6.54% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

DexCom Price Performance

NASDAQ DXCM opened at $70.26 on Thursday. The company has a quick ratio of 1.64, a current ratio of 1.95 and a debt-to-equity ratio of 0.42. The stock has a market capitalization of $27.11 billion, a PE ratio of 30.03, a price-to-earnings-growth ratio of 1.19 and a beta of 1.40. The company has a 50 day moving average price of $63.95 and a two-hundred day moving average price of $66.27. DexCom, Inc. has a 12-month low of $54.11 and a 12-month high of $89.98.

DexCom (NASDAQ:DXCM) last posted its earnings results on Thursday, April 30th. The medical device company reported $0.56 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.47 by $0.09. The firm had revenue of $1.19 billion during the quarter, compared to analysts’ expectations of $1.17 billion. DexCom had a net margin of 19.31% and a return on equity of 33.33%. The company’s revenue was up 15.0% compared to the same quarter last year. During the same period in the previous year, the company earned $0.32 earnings per share. As a group, equities analysts predict that DexCom, Inc. will post 2.57 earnings per share for the current fiscal year.

Institutional Trading of DexCom

A number of institutional investors and hedge funds have recently modified their holdings of the company. Glenmede Trust Co. NA increased its position in DexCom by 36.7% during the first quarter. Glenmede Trust Co. NA now owns 394,751 shares of the medical device company’s stock worth $24,790,000 after acquiring an additional 105,928 shares during the period. Wellington Grp LLC increased its position in DexCom by 778.7% during the first quarter. Wellington Grp LLC now owns 536 shares of the medical device company’s stock worth $34,000 after acquiring an additional 475 shares during the period. Janus Henderson Group PLC increased its position in DexCom by 32.3% during the first quarter. Janus Henderson Group PLC now owns 2,644,539 shares of the medical device company’s stock worth $166,077,000 after acquiring an additional 645,534 shares during the period. Centaurus Financial Inc. bought a new position in DexCom during the first quarter worth $943,000. Finally, Tri Locum Partners LP increased its position in DexCom by 65.6% during the first quarter. Tri Locum Partners LP now owns 698,158 shares of the medical device company’s stock worth $43,844,000 after acquiring an additional 276,558 shares during the period. 97.75% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on DXCM. Sanford C. Bernstein set a $77.00 price objective on shares of DexCom in a research note on Friday, May 1st. Weiss Ratings upgraded shares of DexCom from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Wednesday, March 4th. Benchmark began coverage on shares of DexCom in a research note on Monday, May 11th. They issued a “buy” rating and a $77.00 price objective for the company. Wall Street Zen cut shares of DexCom from a “strong-buy” rating to a “buy” rating in a research note on Sunday, May 10th. Finally, Robert W. Baird set a $80.00 price objective on shares of DexCom in a research note on Friday, May 1st. Three equities research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $82.21.

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.